Lv31
218 积分 2024-06-21 加入
Pharmacodynamic biomarker of CDK4/6 inhibition: prospective evaluation of serum Cyclin D1, CDK4, and CDK6 in palbociclib-letrozole-treated metastatic breast cancer
39分钟前
待确认
Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer
3个月前
已完结
Clinical Activity of RET Tyrosine Kinase Inhibitor (TKI) plus Chemotherapy after Progression on a RET TKI in a RET Fusion–Positive Non–Small Cell Lung Cancer Real-World Cohort: A Brief Report
4个月前
已关闭
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA -mutant breast cancer
4个月前
已完结
Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer
4个月前
已完结
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
4个月前
已完结
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
4个月前
已完结
RET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases
4个月前
已完结
Targeted Therapies for Breast Cancer Brain Metastases
4个月前
已关闭
Ret Receptor Has Distinct Alterations and Functions in Breast Cancer
5个月前
已完结